RT Journal Article
SR Electronic
T1 Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.25.20219337
DO 10.1101/2020.10.25.20219337
A1 Meenu Bajpai
A1 Suresh Kumar
A1 Ashish Maheshwari
A1 Karan Chhabra
A1 Pratibha kale
A1 Amita Gupta
A1 Ashad Narayanan
A1 Ekta Gupta
A1 Nirupama Trehanpati
A1 Chhagan Bihari
A1 Reshu Agarwal
A1 Kamini Gupta
A1 Upendra kumar Gupta
A1 Ankit Bhardwaj
A1 Guresh Kumar
A1 Mojahidul Islam
A1 Ravinder Singh
A1 Pushpa Yadav
A1 Rakhi Maiwall
A1 Shiv Kumar Sarin
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219337.abstract
AB Background The role of convalescent plasma (COPLA) for the treatment of severely ill Corona Virus Disease-2019 is under investigation. We compared the efficacy and safety of convalescent plasma with fresh frozen plasma (FFP) in severe COVID-19 patients.Methods and findings This was an open-label, single-centre phase II RCT on 29 patients with severe COVID-19 from India. One group received COPLA with standard medical care (SMC) (n=14), and another group received FFP with SMC (n=15). A total of 29 patients were randomized in the two treatment groups. Eleven out of 14 (78.5%) patients remained free of ventilation at day seven in the intervention arm while the proportion was 14 out of 15 (93.3 %) in the control arm (p= 0.258). The median reductions in RR per min at 48-hours in COPLA-group and FFP group were -6.5 and -3 respectively [p=0.004] and at day seven were -14.5 and -10 respectively (p=0.008). The median improvements in percentage O2 saturation at 48-hours were 6.5 and 2 respectively [p=0.001] and at day seven were 10 and 7.5 respectively (p=0.026). In the COPLA-group, the median improvement in PaO2/FiO2 was significantly superior to FFP at 48-hours [41.94 and 231.15, p=0.009], and also at day-7 [5.55 and 77.01 p<0.001]. We did not find significant differences in hospitalization duration between the groups (0.08).Conclusion COPLA therapy resulted in rapid improvement in respiratory parameters and shortened time to clinical recovery, although no significant reduction in mortality was observed in this pilot trial. We need larger trials to draw conclusive evidence on the use of Convalescent plasma in COVID-19. This trial is registered with ClinicalTrial.gov (identifier: NCT04346446).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04346446Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Institute of Liver and Biliary Sciences, and IRB of Maulana Azad Medical CollegeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available with Project Investigators at Institute of Liver and Biliary Sciences, and Maulana Azad Medical College and will be available with permission of IRB of above institute